Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ORB-011

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Orionis

Drug class:

Immunomodulator, Dendritic cell activator

Related drugs:

‹

TP53-EphA-2-CAR-DC (0)

personalized cellular vaccine (0)

hydroxychloroquine (7)

quaratusugene ozeplasmid (3)

SQZ-AAC-HPV (1)

HLA-matched donor mononuclear enriched leukocytes (0)

rimiducid activated rivogenlecleucel (0)

GB221 (trastuzumab biosimilar) (0)

GSK2302024A (0)

MVA-BN-HER2 (0)

84AA-API 14AA (0)

nelipepimut-S (0)

engineered donor allograft cell therapy (0)

parvovirus H-1 (0)

FT1050+FT4145 programmed mPB (0)

allodepleted T-cell immunotherapeutics (0)

TAEK-VAC-HerBy vaccine (0)

Undisclosed CISH inactivated TIL (0)

alpha-tocopheroloxyacetic acid (0)

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

HER-2 pulsed DC1 (0)

ilixadencel (0)

KRAS-EphA-2-CAR-DC (0)

TP53-EphA-2-CAR-DC (0)

personalized cellular vaccine (0)

›

over1year

ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=36, Not yet recruiting, Orionis Biosciences Inc

over 1 year ago

New P1 trial • Metastases

|

ORB-011